Archive · 6 Sep 2026
RPG Life Sciences Plans ₹500 Crore Expansion Through Acquisitions
RPG Life Sciences is a medicine company that wants to grow bigger.
It plans to spend ₹500 crore during the next year.
The money will help it improve factories and make more active pharmaceutical ingredients, or APIs.
The company has already bought assets worth ₹200 crore as part of a larger ₹700 crore expansion plan.
It hopes to earn ₹2,000 crore-₹2,500 crore in revenue by 2030.
Its domestic medicine business makes up about 70% of its total business.
The company said sales grew 16% and EBITDA grew 18% in the first quarter of FY27.
It is also entering West Africa and the Saudi region.
Its managing director said the market for GLP-1 anti-obesity medicines is still at an early stage.
RPG Life Sciences plans to deploy ₹500 crore over the next 12 months to expand manufacturing and API capabilities.
The company has committed ₹700 crore for expansion and has already made acquisitions worth ₹200 crore.
Managing Director Ashok Nair said the company is evaluating assets that could strengthen its manufacturing footprint.
RPG Life Sciences targets revenue of ₹2,000 crore-₹2,500 crore by 2030, with APIs expected to play a larger role.
The company reported 16% revenue growth and 18% EBITDA growth in the first quarter of FY27.
- Who
- RPG Life Sciences and its Managing Director Ashok Nair.
- What
- The company plans to deploy ₹500 crore on acquisitions and expansion of manufacturing and API capabilities.
- When
- The investment is planned over the next 12 months; the update was reported on September 6.
- Where
- The company operates in India and more than 60 international countries, excluding the United States, and is entering West Africa and the Saudi region.
- Why
- To strengthen its manufacturing footprint, expand API capabilities, and support its revenue target for 2030.
- Planned deployment
- ₹500 crore over the next 12 months
- Committed capital infusion
- ₹700 crore
- Acquisitions completed or made
- Approximately ₹200 crore
- 2030 revenue target
- ₹2,000 crore-₹2,500 crore
- First-quarter revenue growth
- 16% in FY27
- First-quarter EBITDA growth
- 18% in FY27
- EBITDA margin
- 24.5%, compared with 24.1% previously